Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Radius completes enrollment in phase II clinical trial of BA-058 for osteoporosis

April 7, 2008

Recent patents impart novel metabolic drugs

April 7, 2008

EMEA approves Forsteo for treatment of glucocorticoid-induced osteoporosis

April 7, 2008

Enhanced lipid effects seen with ezetimibe/simvastatin plus niacin in hyperlipidemia

April 7, 2008

The FDA accepts FibroGen's complete response for clinical holds of FG-2216 and FG-4592

April 4, 2008

Teijin enters license agreement in Japan with Dong Wha for DW-1350 in osteoporosis

April 4, 2008

ABT-335 and statin combinations effective in phase III dyslipidemia studies

April 4, 2008

Repros reports interim safety results from study of Proellex in uterine fibroids

April 3, 2008

Dalcetrapib safe in phase II hyperlipidemia studies

April 3, 2008

TAK-475 development for hypercholesterolemia discontinued

April 2, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...